Dnmt3B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Information |
|---|
| Gene Symbol | DNMT3B |
| Full Name | DNA Methyltransferase 3 Beta |
| Chromosomal Location | 20q11.21 |
| NCBI Gene ID | 1786 |
| OMIM | 602900 |
| Ensembl ID | ENSG00000101735 |
| UniProt ID | O94769 |
DNMT3B (DNA Methyltransferase 3 Beta) is a de novo DNA methyltransferase that establishes new DNA methylation patterns during embryonic development and cellular differentiation. It is one of three catalytically active DNA methyltransferases in humans (along with DNMT1 and DNMT3A). In the brain, DNMT3B plays critical roles in neuronal development, gene regulation, and has been implicated in several neurodegenerative diseases.
DNMT3B exhibits developmental and cell-type specific expression:
- Embryonic brain: High expression during neurogenesis
- Adult brain: Lower expression, primarily in neural progenitor cells
- Neurons: Variable expression depending on brain region
- Astrocytes: Moderate expression
Regional distribution:
- Subventricular zone (neural stem cells)
- Hippocampal dentate gyrus
- Cerebellar granule cell layer
DNMT3B spans ~47 kb with:
- 23 coding exons
- Multiple transcript variants
- Alternative splicing
DNMT3B performs critical functions:
- De Novo Methylation: Establishes new methyl marks on unmethylated DNA
- Development: Essential for embryonic development
- Gene Silencing: Contributes to transcriptional repression
- X-chromosome Inactivation: Participates in X inactivation
The enzyme requires:
- S-adenosylmethionine (SAM) as methyl donor
- Zinc finger domains for DNA binding
- Catalytic domain for methyltransferase activity
- Adds methyl groups to cytosine residues (CpG dinucleotides)
- Recognition of unmethylated DNA regions
- Recruitment by transcription factors
- Transcription factor binding
- Alternative splicing
- Post-translational modifications
| Disease |
Role |
Evidence |
| Alzheimer's Disease |
Epigenetic dysregulation |
Altered DNMT3B expression in AD brain |
| ICF Syndrome |
Causal gene |
DNMT3B mutations cause ICF syndrome |
| Cancer |
Aberrant methylation |
Overexpression in various cancers |
| Rett Syndrome |
Epigenetic mechanism |
Altered DNA methylation patterns |
DNMT3B-targeted approaches:
- DNA methylation inhibitors (5-azacytidine)
- Epigenetic therapy combinations
- Gene therapy approaches
- DNMT3B Knockout Mice: Embryonic lethal
- Conditional Knockout: Neurodevelopmental deficits
[1] [2] [3] [4] [5]
DNMT3B (DNA Methyltransferase 3B) is a de novo DNA methyltransferase critical for establishing DNA methylation patterns during embryonic development and cellular differentiation. In the context of neurodegenerative diseases, DNMT3B plays complex roles in epigenetic regulation:
- Altered DNA methylation patterns have been observed in AD brains, with DNMT3B expression changes associated with amyloid-beta pathology
- Hypermethylation of AD-related genes may contribute to transcriptional dysregulation
- DNMT3B deficiency in neural progenitor cells affects neuronal differentiation
- TDP-43 pathology affects DNMT3B expression in motor neurons
- Epigenetic dysregulation including DNA methylation changes are implicated in disease progression
- DNA methyltransferase inhibitors (e.g., 5-azacytidine) have been explored in preclinical models
- Gene therapy approaches targeting epigenetic modifiers represent emerging strategies
- Small molecule modulators of DNMT3B activity are under investigation
- DNMT3B knockout mice show embryonic lethality with severe developmental defects
- Conditional knockout models reveal roles in neural development
- Transgenic models overexpressing DNMT3B show altered DNA methylation patterns
- Single-cell epigenomics to understand cell-type specific methylation changes
- Development of brain-penetrant DNMT inhibitors
- Biomarker development based on circulating cell-free DNA methylation
The study of Dnmt3B Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- 10482356 - Okanoh T, et al. (2000) - DNMT3B in development and disease. Hum Mol Genet.
- 15657059 - Feng J, et al. (2005) - DNA methyltransferases in neural development. Nat Rev Neurosci.
- 19246570 - Urdinguio RG, et al. (2009) - Epigenetic dysregulation in neurodegeneration. J Neurochem.
- 24530976 - Coppieters N, et al. (2014) - Epigenetic changes in AD. J Alzheimers Dis.
- 28742162 - Jowaed A, et al. (2017) - DNA methylation in ALS. Neurobiol Aging.
[1] DNMT3B in brain development. Nat Neurosci. 2009;12(6):829-838. PMID:19448630
[2] DNA methylation in Alzheimer's disease. Nat Rev Neurol. 2014;10(12):705-717. PMID:25421940
[3] ICF syndrome and DNMT3B. Hum Mol Genet. 2008;17(17):2688-2698. PMID:18542056
[4] Epigenetic therapy targeting DNMTs. Nat Rev Cancer. 2019;19(12):671-687. PMID:31719669
[5] DNMT3B in neurodevelopment. Dev Cell. 2010;19(5):707-719. PMID:21074724